Literature DB >> 22115643

CHADS(2) and CHA(2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation.

Tze-Fan Chao1, Yenn-Jiang Lin, Hsuan-Ming Tsao, Chin-Feng Tsai, Wei-Shiang Lin, Shih-Lin Chang, Li-Wei Lo, Yu-Feng Hu, Ta-Chuan Tuan, Kazuyoshi Suenari, Cheng-Hung Li, Beny Hartono, Hung-Yu Chang, Kibos Ambrose, Tsu-Juey Wu, Shih-Ann Chen.   

Abstract

OBJECTIVES: This study aimed to evaluate whether CHADS(2) and CHA(2)DS(2)-VASc scores are useful for risk stratification in patients after catheter ablation of atrial fibrillation (AF).
BACKGROUND: AF is associated with increased risk of cardiovascular events. However, limited data are available on the predictors of adverse events in patients with AF after catheter ablation.
METHODS: A total of 565 patients with AF who underwent catheter ablation were enrolled in the study. The clinical endpoint was occurrence of thromboembolic events (ischemic stroke, transient ischemic attack, peripheral embolism, or pulmonary embolisms) or death during follow-up after catheter ablation.
RESULTS: During a follow-up of 39.2 ± 22.6 months, 27 patients (4.8%) experienced adverse events. Both the CHADS(2) and CHA(2)DS(2)-VASc scores were useful predictors of events in separate multivariate models. The areas under the receiver-operator characteristic curves based on the CHADS(2) and CHA(2)DS(2)-VASc scores in predicting events were 0.785 and 0.830, respectively. Although the difference did not reach statistical significance (p = 0.116), the CHA(2)DS(2)-VASc score could be used to further stratify the patients with CHADS(2) scores of 0 or 1 into 2 groups with different event rates (7.1% vs. 1.1%, p = 0.003) at a cutoff value of 2.
CONCLUSIONS: The CHADS(2) and CHA(2)DS(2)-VASc scores are useful predictors of adverse events after catheter ablation of AF.
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22115643     DOI: 10.1016/j.jacc.2011.08.045

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  39 in total

1.  Rationale and design of the ODIn-AF Trial: randomized evaluation of the prevention of silent cerebral thromboembolism by oral anticoagulation with dabigatran after pulmonary vein isolation for atrial fibrillation.

Authors:  Jan W Schrickel; Markus Linhart; Dietmar Bänsch; Daniel Thomas; Georg Nickenig
Journal:  Clin Res Cardiol       Date:  2015-10-29       Impact factor: 5.460

2.  [Pre-interventional, peri-interventional and post-interventional anticoagulation in the setting of catheter ablation for atrial fibrillation : current practice and practical approach].

Authors:  M Antz; S Willems; B A Hoffmann
Journal:  Herz       Date:  2015-02       Impact factor: 1.443

3.  Predicting Left Atrial Appendage Thrombus from Left Atrial Volume and Confirmation by Computed Tomography with Delayed Enhancement.

Authors:  Kazuhiro Osawa; Rine Nakanishi; Indre Ceponiene; Negin Nezarat; William J French; Matthew J Budoff
Journal:  Tex Heart Inst J       Date:  2020-04-01

Review 4.  Clinical scores used for the prediction of negative events in patients undergoing catheter ablation for atrial fibrillation.

Authors:  Falco Kosich; Katja Schumacher; Tatjana Potpara; Gregory Y Lip; Gerhard Hindricks; Jelena Kornej
Journal:  Clin Cardiol       Date:  2019-01-14       Impact factor: 2.882

5.  Combination of Oral Anticoagulants and Single Antiplatelets versus Triple Therapy in Nonvalvular Atrial Fibrillation and Acute Coronary Syndrome: Stroke Prevention among Asians.

Authors:  Anwar Santoso; Sunu B Raharjo
Journal:  Int J Angiol       Date:  2020-05-06

Review 6.  2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design.

Authors:  Hugh Calkins; Karl Heinz Kuck; Riccardo Cappato; Josep Brugada; A John Camm; Shih-Ann Chen; Harry J G Crijns; Ralph J Damiano; D Wyn Davies; John DiMarco; James Edgerton; Kenneth Ellenbogen; Michael D Ezekowitz; David E Haines; Michel Haissaguerre; Gerhard Hindricks; Yoshito Iesaka; Warren Jackman; Jose Jalife; Pierre Jais; Jonathan Kalman; David Keane; Young-Hoon Kim; Paulus Kirchhof; George Klein; Hans Kottkamp; Koichiro Kumagai; Bruce D Lindsay; Moussa Mansour; Francis E Marchlinski; Patrick M McCarthy; J Lluis Mont; Fred Morady; Koonlawee Nademanee; Hiroshi Nakagawa; Andrea Natale; Stanley Nattel; Douglas L Packer; Carlo Pappone; Eric Prystowsky; Antonio Raviele; Vivek Reddy; Jeremy N Ruskin; Richard J Shemin; Hsuan-Ming Tsao; David Wilber
Journal:  J Interv Card Electrophysiol       Date:  2012-03       Impact factor: 1.900

Review 7.  EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  Heart Rhythm       Date:  2016-06-10       Impact factor: 6.343

Review 8.  Incorporating Stroke and Bleeding Risk Stratification Tools into Atrial Fibrillation Management Making Sense of the Alphabet Soup.

Authors:  Thomas F Deering
Journal:  J Atr Fibrillation       Date:  2017-04-30

Review 9.  Catheter ablation of atrial fibrillation to reduce stroke risk.

Authors:  B Schmidt; S Bordignon; A Fürnkranz; K R J Chun
Journal:  Herz       Date:  2013-05       Impact factor: 1.443

10.  Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group.

Authors:  Valentin Fuster; Deepak L Bhatt; Robert M Califf; Alan D Michelson; Marc S Sabatine; Dominick J Angiolillo; Eric R Bates; David J Cohen; Barry S Coller; Bruce Furie; Jean-Sebastien Hulot; Kenneth G Mann; Jessica L Mega; Kiran Musunuru; Christopher J O'Donnell; Matthew J Price; David J Schneider; Daniel I Simon; Jeffrey I Weitz; Marlene S Williams; W Keith Hoots; Yves D Rosenberg; Ahmed A K Hasan
Journal:  Circulation       Date:  2012-09-25       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.